

Human Papillomavirus vaccination in general practice in France, three years after the implementation of a targeted vaccine recommendation based on age and sexual history

Pascale Thierry, Andrea Lasserre, Louise Rossignol, Solen Kernéis, Fanette Blaizeau, Chantal Stheneur, Thierry Blanchon, Daniel Levy-Bruhl, Thomas Hanslik

► To cite this version:

Pascale Thierry, Andrea Lasserre, Louise Rossignol, Solen Kernéis, Fanette Blaizeau, et al.. Human Papillomavirus vaccination in general practice in France, three years after the implementation of a targeted vaccine recommendation based on age and sexual history: Targeted HPV vaccine recommendation in France. Human vaccines

immunotherapeutics. (Hum Vaccin Immunother), 2015-: Philadelphia, PA : Taylor

Francis, 2015, <10.1080/21645515.2015.1078042>. <inserm-01246163>

HAL Id: inserm-01246163

<http://www.hal.inserm.fr/inserm-01246163>

Submitted on 18 Dec 2015

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Human Papillomavirus vaccination in general practice in France, three years after the implementation of a targeted vaccine recommendation based on age and sexual history

Pascale Thierry^{1,2}, Andrea Lasserre^{1,2}, Louise Rossignol^{1,2}, Solen Kernéis^{1,2}, Fanette Blaizeau^{1,2}, Chantal Stheneur⁴, Thierry Blanchon^{1,2}, Daniel Levy-Bruhl⁵, Thomas Hanslik^{3,6}

¹INSERM, UMR_S 1136, F-75012, Paris

²Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, F-75012, Paris, France

³Assistance Publique Hôpitaux de Paris, service de Pédiatrie, Hôpital Ambroise Paré, Boulogne Billancourt, F-92100, France

⁴Institut de Veille Sanitaire, Département des Maladies Infectieuses, Saint-Maurice, F-94410, France

⁵Assistance Publique Hôpitaux de Paris, service de Médecine Interne, Hôpital Ambroise Paré, Boulogne Billancourt, F-92100, France

⁶Université Versailles Saint Quentin en Yvelines, Versailles, F-78000, France

Running head: Targeted HPV vaccine recommendation in France

Corresponding author:

Thomas Hanslik

Service de Médecine Interne, Hôpital Ambroise Paré

92104 Boulogne Billancourt cedex

France

Tel: +33 1 49 09 56 38

Email: thomas.hanslik@apr.aphp.fr

Abstract

Introduction

In France, vaccination against human papilloma virus (HPV) was recommended in 2007 for all 14-year-old girls as well as “catch-up” vaccination for girls between 15-23 years of age either before or within one year of becoming sexually active. We evaluated the vaccine coverage according to the eligibility for vaccination in a sample of young girls aged 14 to 23 years, who were seen in general practices.

Patients and methods

A survey was proposed to 706 general practitioners (GPs) and carried out from July to September 2010. GPs, also called “family doctor”, are physicians whose practice is not restricted to a specific field of medicine but instead covers a variety of medical problems in patients of all ages. Each participating GP included, retrospectively, the last female patient aged 14-17 years and the last female patient aged 18-23 years whom he had seen. A questionnaire collected information regarding the GP and the patients’ characteristics. The vaccine coverage was determined according to the eligibility for vaccination, i.e. the coverage among younger women (14-17) and among those sexually active in the second age range (18-23). Sexual activity status was assessed by GP, according to information stated in the medical record.

Results

The 363 participating physicians (response rate 51.4%) included 712 patients (357 in the 14- to 17-year-old group and 355 in the 15- to 23-year-old group) in their responses. The rate of the vaccination coverage in the 14- to 17-year-old group was 55%. Among the girls in the 18- to 23-year-old group, 126 were eligible, and their vaccination coverage rate was 82%. The evaluation of the eligibility by the GPs was incorrect in 36% of the cases. Of the 712 patients, 6% of the girls had been vaccinated without a need for the vaccination, and 26% of the girls had not been vaccinated, although they needed to be vaccinated.

Discussion

Regarding the vaccine uptake, vaccination at the age of 14 was not as effective as vaccinating the older population for which vaccination was indicated as a catch-up program, based on sexual history. However, in more than one-third of the older population, difficulties remained regarding the determination of eligibility, according to the sexual history of the patient.

INTRODUCTION

In France, vaccination against HPV (human papilloma virus) was recommended in 2007 for all 14-year-old girls and as a “catch-up” vaccination for girls between 15 and 23 years of age before the first time they have sex or within one year of becoming sexually active.¹ This restriction regarding the sexual activity was specific to France. In most developed countries, vaccination is recommended for all girls with the target age varying between 9 and 14 years of age, occasionally with a catch-up vaccination in older women.²

The rate of administration of the HPV vaccine in ambulatory medical practices in France is difficult to evaluate. The routine data that exist are only for girls between 14 and 17 years of age, independent of their sexual activity. Between 2008 and 2011 vaccination coverage has been estimated between 17 to 54%.³⁻⁸ This vaccination is offered almost exclusively by private practitioners—mainly general practitioners (GPs) and gynecologists. Past studies have shown a very good level of acceptance of the HPV vaccine by French GPs and their patients: nearly 90% of GPs had a favorable opinion,^{9, 10} and more than 75% of young girls were favorable toward this vaccination.^{3-6, 11} The main reluctance mentioned by young girls results from a lack of knowledge regarding the vaccination, the cost of the vaccine, the fear of adverse events and parental refusal.^{3,4} The paradox between the good level of acceptance and the insufficient vaccination coverage shows that there are other barriers to this vaccination. It can be questioned whether the recommendation, based on not only age, but also on sexual activity, could impact vaccination coverage. In that context, we evaluated the vaccine coverage, according to eligibility for vaccination in a sample of girls who were seen in general practices in mainland France.

The French health care system is based on a universal “social security” system funded by the government, employers, and the working population. Social security health insurance covers the cost of general and specialized medical consultations, drugs prescription (including vaccines), laboratory analyses, and hospitalization. In the case of HPV vaccine, it provides reimbursement of 65% of its cost

(123.44 euros per dose) to those who are insured. Private health insurances may be subscribed to reimburse health related costs not covered by the social security. For the most disadvantaged, state-run programs provides universal health coverage. For them, reimbursement of HPV vaccine is at 100%.

PATIENTS AND METHODS

A national retrospective study was conducted in 2010 by the GPs of the Sentinelles network(<http://www.sentiweb.fr>). The retrospective nature of the study was essential to avoid any modification of the practices by the GP. The Sentinelles network is a computerized disease surveillance system that is located throughout mainland France and participates both in the surveillance of 10 health indicators and in epidemiological studies.^{12, 13} A postal survey was proposed to 706 GPs (i.e., the GPs of the Sentinelles network who had accepted to participate at least once in previous epidemiological studies conducted in this network over the preceding five years).

Each participating GP was asked to retrospectively include the last two female patients seen for a consultation: the last 14- to 17-year-old (all of whom turned 14 years old between 2007 and 2010) and the last 18- to 23-year-old.

The participating GPs responded to a postal questionnaire on each included patient. Information regarding the attitudes toward the HPV vaccine, eligibility, and vaccination status of the included patient was collected. Each questionnaire was completed from the medical record.

All girls in the 14- to 17-year-old group were or at least had been eligible because they all turned 14 years old between 2007 and 2010. Among the 18- to 23-year-old group, girls were eligible if sexual activity had not begun or had existed for less than 1 year and if they were 15 years or older in 2007. For the patients who were already vaccinated, the eligibility was retrospectively verified at the time of vaccination. For the non-vaccinated patients, the eligibility was defined, according to their age and

sexual history on the day of the survey. The sexual history was evaluated, according to the information reported by the GPs, based on their medical records.

The GPs were asked to mention which of the non-vaccinated patients in the 18- to 23-year-old group they thought belonged to the population for which the vaccination was recommended, based on the information that they had available for each patient. This information was qualified as “eligibility according to the GPs”, which reflects the understanding and knowledge of the vaccination against HPV recommendations. The concordance between the “eligibility” of the patient for the HPV vaccine, according to the French guidelines and the eligibility according to the GP was estimated by a kappa test, which was interpreted according to the Landis and Koch ranking.¹⁴

The patients were considered vaccinated against HPV if they had received at least one injection of the vaccine. The patients for whom the vaccination status was unknown by the GP were considered not vaccinated for the data analysis.

The transmitted data were anonymized and entered into the EPIDATA software. The data quality was checked, and every meaningless value was corrected. If necessary, the GPs were called to complete the missing data. The analysis of the data was conducted using the STATA software.

RESULTS

Of the 706 GPs whom we approached, 363 (51.4%) participated. Their average age was 53.5 years, and 80% were male. Among these GPs, 344 declared that they felt very comfortable or rather comfortable in providing care for teenagers (95%); 302 declared that the HPV vaccine was useful or very useful (83%) and 349 were reported to be slightly worried or not worried regarding side effects of the HPV vaccine (96%). Characteristics of GPs and included girls are presented in Tables 1 and 2.

The participating GPs included 712 patients in their care as follows: 357 (50.1%) in the 14- to 17-year-old group and 355 (49.9%) in the 18- to 23-year-old group.

All girls in the 14- to 17-year-old group were or had been eligible at the time of the study. Among the 18- to 23-year-old group, girls were eligible according to their sexual activity as reported by the GP.

In the 18- to 23-year-old group, 126 patients (35%) were eligible for the HPV vaccine, 137 (49%) were not eligible (sexual activity for more than one year) and for 92 patients (26%), the eligibility could not be determined because their sexual activity was unknown. The vaccination status of patients, according to their eligibility, is represented in Figure 1.

Of the 341 vaccinated patients (Table 3), 196 were between 14 and 17 years old, and 145 were between 18 and 23 years old. Among the 196 subjects vaccinated in the 14- to 17-year-old group, they were all eligible for the HPV vaccine. Among the 145 subjects vaccinated against HPV in the 18- to 23-year-old group, 103 were eligible for the HPV vaccine on the day of the vaccination (71%), 30 were not eligible (21%), and the eligibility was undetermined for 12 girls (8%). Thus, among the 341 total vaccinated subjects, 299 (88%) were eligible, 30 (9%) were not eligible, and the eligibility was undetermined for 12 (3%).

Of the 371 unvaccinated patients (Table 3), 161 were between 14 and 17 years old, and 210 were between 18 and 23 years old. Among the 161 patients who were not vaccinated against HPV in the 14- to 17-year-old group, all were (or had been) eligible for the HPV vaccine. Among the 210 subjects who were not vaccinated against HPV in the 18- to 23-year-old group, 23 were eligible for the HPV vaccine on the day of the study (11%), 125 were not eligible (59%) and the eligibility was undetermined for 62 (30%). Among the 371 total unvaccinated subjects, 184 (49%) were eligible, 125 (34%) were not eligible, and the eligibility was undetermined for 62 (17%).

GPs had to answer for each girl if HPV vaccine was recommended or not. This was considered "eligibility according to the GPs". "Real eligibility" was assessed by researchers, according to information of age and sexual activity reported by (i.e. available to) the GP. The evaluation of

eligibility by GPs was wrong in 36% of the cases. The concordance between the real eligibility and the eligibility according to the GPs was low (kappa was 0.36).

Of the 483 patients eligible for the HPV vaccine, 299 were vaccinated (67%) as follows: 55% in the 14- to 17-year-old group and 82% in the 18- to 23-year-old group.

DISCUSSION

Three years after the implementation of a targeted HPV vaccination recommendation, based on age and sexual history, vaccination coverage of eligible patients was 67%. The vaccination rate was higher in the catch-up age group. GPs correctly evaluated the eligibility for vaccination in two-thirds of the patients; however, they lacked data on the sexual activity and, thus, on the eligibility for vaccination in 26% of the cases, predominantly in the catch-up age group.

The vaccination coverage was 67% for all of the eligible patients (every age group), 55% for the 14- to 17-year-old girls who were (or had been) eligible, and 82% in the catch-up age group (eligible girls who were 18-23 years old). In 2009, the vaccination coverage was 25% among a sample of adolescents (a mean age of 16 years old).⁴ According to another study conducted in 2009, the vaccination coverage was estimated at 33% among 14-year-old and 54% among 17-year-old adolescents, which is quite close to our results.⁵ Based on the refunding data and regarding the vaccines by the French Social Security System, the vaccination coverage among the 14-to-23-year-old girls in Paris was 17% in 2009.⁶ The results are close to those obtained for the 14- to 17-year-old girls; however, they were different for the 18- to 23-year-old eligible patients. That the older age group had higher vaccination coverage than the younger group might suggest that GPs are more comfortable discussing a vaccination linked to sexual activity with older patients.¹¹ The concordance between the real eligibility of the patient and the eligibility according to the GP was low. It was not possible to establish the eligibility of 26% of the patients in the 18- to 23-year-old group. These data

show that for the catch-up vaccination, establishing eligibility based on the current recommendations is not always easy in practice.

The implementation of the HPV vaccine had varied in different countries. The vaccination coverage rates of ≥ 1 dose of any HPV vaccine in the USA, Germany, and Sicily were 57.3%, 47.6%, and 43.1%, respectively.¹⁴⁻¹⁶ Access to the HPV vaccine is shaped by decisions at different levels of the socio-ecological model, including the policy context, social norms and values, views and actions of healthcare professionals, and parental consent.¹⁷ An important facilitator of HPV vaccination appears to be the decision of a healthcare professional to recommend vaccination.¹⁷ The simpler the recommendations are, the better is the adherence.¹⁸ In our study, the analysis of the determinants of the HPV vaccination was carried separately for the two groups of patients (14- to 17-years-old and 18- to 23-years-old). None of the examined characteristics were associated with HPV vaccination status (data not shown). HPV vaccine is strongly related to sexuality and raises issues that interest young teenagers, their parents, and society.

Several studies about the optimal age for HPV vaccine have been published with heterogeneous results. Having to address sexuality has an impact on acceptability of vaccination for young teenagers, their parents and their doctor, and thereby, on the most acceptable age for vaccination. Studies have showed different perceptions, according to the countries where they were conducted, or even within the same country where several studies were conducted. For example, according to the majority of participants, the ideal age for vaccination was before 13 years in California.¹⁹ Another study conducted in the United States discovered those surveyed favoured "during adolescence and not pre-adolescence".²⁰ In other countries, preferred ages are between 15 and 17 years in Sweden,²¹ between 12 and 16 years in Belgium,^{22, 23} and at the age of 13 or beyond in New Zealand.²⁴ Overall, opinions are divided between supporters of vaccination at a later age who go along with the provision of information on sexuality and STDs and supporters of early vaccination who avoid addressing this issue. A recommendation with a wider range of ages allows more flexibility, leaving

the physician, the patient and her parent(s) to decide to offer vaccination at the age that seems most appropriate to each situation.

This study has some limitations. First, the vaccination coverage of the catch-up group might be overestimated because the patients for whom the eligibility could not be determined (predominantly because the GP did not know the sexual history of the patients) were not considered when calculating the vaccination coverage. It is likely that the GPs with better knowledge of the eligibility of a patient were more prone to give her the vaccine. Second, girls with unknown vaccination status were considered non-vaccinated, which might underestimate vaccination coverage. Nevertheless, it is important to note that two French studies reported that the majority of HPV vaccine were done by GPs (82.84 to 92% of cases),^{25,26} Third is the questionable ascertainment of eligibility for vaccination. Indeed, we compared eligibility estimated by the physician and eligibility based on the information about sexual activity found in the routine records of the medical doctors. It is not clear what the true situation is. The problem could go in both directions - doctors not being aware of sexual activity status or patients reporting false information about activity. However, our study was a "real life" ascertainment and represented the way that the vaccination recommendation was implemented "in the field": the physician reported his or her understanding of eligibility, and the true eligibility was determined, according to information that was indeed available to the physician. Thus, we considered that this ascertained eligibility was representative of the understanding and implementation of vaccine recommendation by the GPs in real life, which was the scope of the study. Fourth, eligibility based on information stated in the medical record could have an impact on the estimation of the vaccine coverage because registration of sexual initiation may be heterogeneous; but it could over or underestimate the results. Fifth, this study was conducted in a population of girls who consulted a GP and not in a group of girls from the general population. It is likely that these young girls have, on average, a more regular medical follow-up than do young girls without follow-up by a GP. Sixth, it is possible that girls who do not consult a GP have different sexual behaviours. Seventh, the participating GPs were part of a health-monitoring network: the GPs who

participated in this study might be more concerned regarding vaccination and HPV infection than non-responders, and their practices might differ. The demographic characteristics of and the number of patients seen daily by Sentinelles GPs are consistent with those of all French GPs.²⁷ However, among the participating physicians here, male GPs were over represented (80%, versus 69% in all French GPs in 2010²⁸). We could hypothesize that female and male practices are different regarding HPV vaccination, but in our study there was no association between HPV vaccination status of patients and GP's gender.

To our knowledge, this study is the first to estimate vaccination coverage according to eligibility in the context of targeted vaccination based on age and sexual history. It showed that the vaccine uptake in the older population for which the vaccination was indicated as a catch-up program, was higher than in the targeted 14-year old patients. Even if difficulties remained for the GPs to establish eligibility according to sexual history, they were more successful in convincing girls reaching the age of sexual activity than younger adolescents to be vaccinated. The French recommendations for vaccination against HPV changed in 2013²⁹ as follows: vaccination is now recommended for girls aged 11 to 14 years and as a "catch-up" vaccination for girls aged 15 and 20 years without any limitation by sexual activity. Vaccination from 11 years of age allows initiation of the HPV vaccination at the same time as other vaccinations that are typically provided at this age. It is hoped that this new vaccination strategy will increase the coverage of girls less than 17 years of age, which is currently very low.

Table 1: Characteristics and attitudes of general practitioners

Characteristics	n (%)
Demographic characteristics, N = 354*	
Sex : Male versus Female	262 (80) vs 72 (20)
Age, median (years)	55
Attitudes towards Human papillomavirus (HPV) vaccine and gynecology consultation, N=363	
Documentation about HPV vaccine in the waiting room	
Yes	200 (55)
Pap smear practice: (missing data =1)	
Never	77 (21)
Rarely	35 (10)
Occasionally	111 (31)
Often	139 (38)
Contraceptive Initiation	
Never	3 (1)
Rarely	23 (6)
Occasionally	133 (37)
Often	204 (56)
Opinion towards HPV vaccine, N=363	
Facility in the care of adolescents: (missing data =2)	
Not at all comfortable	0 (0)
Not very comfortable	17 (5)
Somewhat comfortable	250 (69)
Very comfortable	94 (26)
Age appropriate to talk about sexuality :	
12-14 years	51 (14)
14-17 years	220 (61)
More than 17 years	32 (9)
Never approach the subject itself	19 (5)
Do not know	41 (11)
Felt the usefulness of anti- HPV vaccine	
Not at all useful	8 (2)
Moderately useful	53 (15)
Helpful	128 (35)
Very useful	174 (48)
Anxiety-related side effects of HPV vaccine: (missing data =1)	
Not at all worried	240 (66)
A bit worried	109 (30)
Worried	10 (3)
Very worried	3 (1)

*Nine doctors do not identify themselves on the form, so their demographic data could not be determined.


Table 2: Characteristics of included girls

Characteristics	14-17 group n(%) N = 357	18-23 group n(%) N = 355
Parent's socio-professional category		
Farmers	20 (6)	20 (6)
Artisans, merchants, entrepreneurs	37 (10)	29 (8)
Higher managerial and professional occupations	74 (21)	67 (19)
Intermediate occupations (clerical, sales, service)	53 (15)	44 (12)
Small employers and own account workers	86 (24)	91 (26)
Lower supervisory and technical occupations	39 (11)	37 (10)
Retirees	3 (1)	3 (1)
Never worked and long-term unemployed	27 (7)	28 (8)
Do not know	18 (5)	36 (10)
Living place: (missing data for 18-23 group = 15)		
Alone	2 (1)	46 (14)
With her parent	348 (97)	203 (60)
In a couple	1 (0)	84 (25)
Other	6 (2)	7 (2)

Table 3: Eligibility to HPV vaccine according to vaccination status.

Age Group (years)	Eligible			Not eligible	Unknown eligibility	Total
	14-17	18-23	All	18-23	18-23	14-23
Vaccinated	196 (55%)	103 (82%)	299 (62%)	12 (9%)	30 (33%)	341 (48%)
Unvaccinated or unknown vaccination status	161 (45%)	23 (18%)	184 (38%)	125 (91%)	62 (67%)	371 (52%)

Figure 1:Flow chart and vaccination status according to eligibility and age (HPV: human papilloma virus)



REFERENCE

1. Haute Autorité de Santé. Recommandation du Collège de la Haute Autorité de Santé [sur les vaccins Gardasil® et Cervarix®]. 2008 April. Available from: <http://www.snfge.org/download/file/fid/345>.
2. Wright TC, Jr., Huh WK, Monk BJ, Smith JS, Ault K, Herzog TJ. Age considerations when vaccinating against HPV. *Gynecol Oncol*. 2008 May;109(2 Suppl):S40-7. doi: 10.1016/j.ygyno.2008.02.002. PubMed PMID: 18482558. Epub 2014 Feb 19.
3. Mehu-Parant F, Rouzier R, Soulat JM, Parant O. Eligibility and willingness of first-year students entering university to participate in a HPV vaccination catch-up program. *Eur J Obstet Gynecol Reprod Biol*. 2009 Feb;148(2):186-90. doi: 10.1016/j.ejogrb.2009.10.024. PubMed PMID: 19926199. Epub 2009 Nov 18.
4. Lerais I, Durant M, Gardella F, Hofliger P, Pradier C, Giordanengo V, et al. Survey of knowledge, beliefs, and behaviors of students around the human papillomavirus. *Bull Epidemiol Hebd*. 2010;11:97-101.
5. INPES. Baromètre santé médecins généralistes. 2009.
6. Rouzier R, Giordanella JP. Coverage and compliance of human papilloma virus vaccines in Paris: demonstration of low compliance with non-school-based approaches. *J Adolesc Health*. 2010 Sep;47(3):237-41. doi: 10.1016/j.jadohealth.2010.04.006. PubMed PMID: 20708561. Epub 2010 Jun 17.
7. Sanitaire IdV. Estimated vaccination coverage in private practice in France 2004-2009 2010. Available from: http://opac.invs.sante.fr/doc_num.php?explnum_id=248.
8. Fonteneau L, Guthmann JP, D LB. Estimation des couvertures vaccinales en France à partir de l'Échantillon généraliste des bénéficiaires (EGB): exemples de la rougeole, de l'hépatite B et de la vaccination HPV. Numéro thématique. De nouveaux outils pour améliorer la mesure de la couverture vaccinale en France. *Bull Epidemiol Hebd*. 2013;8-9:72-6.
9. Pelissier G, Bastides F. Vaccination anti-HPV dans le cadre de la prévention du cancer du col de l'uterus en medecine generale. Enqueteréaliseeaupres des medecinsgeneralistes d'Eure-et-Loir et du Cher [HPV vaccine and cervical cancer prevention in general practice. Survey conducted among general practitioners in the French departments of Eure-et-Loir and Cher]. *Rev Prat*. 2008 Dec 15;58(19 Suppl):25-31. PubMed PMID: 19253788. Epub 2009 Mar 4.
10. Piana L, Noel G, Uters M, Laporte R, Minodier P. Opinions et pratiques des medecinsgeneralistes face a la vaccination anti-papillomavirus [Standpoint and practice concerning the human papillomavirus vaccine among French family physicians]. *Med Mal Infect*. 2009 Oct;39(10):789-97. doi: 10.1016/j.medmal.2009.08.007. PubMed PMID: 19796892. Epub 2009 Sep 30.
11. Lutringer-Magnin D, Kalecinski J, Barone G, Leocmach Y, Regnier V, Jacquard AC, et al. Human papillomavirus (HPV) vaccination: perception and practice among French general practitioners in the year since licensing. *Vaccine*. 2011 Jul 18;29(32):5322-8. doi: 10.1016/j.vaccine.2011.05.006. PubMed PMID: 21616114. Epub 2011 May 25.
12. Flahault A, Blanchon T, Dorleans Y, Toubiana L, Vibert JF, Valleron AJ. Virtual surveillance of communicable diseases: a 20-year experience in France. *Stat Methods Med Res*. 2006 Oct;15(5):413-21. PubMed PMID: 17089946. Epub 2006 Nov 9.
13. Network FGS. Annual report 2009. Available from: <http://websenti.u707.jussieu.fr/sentiweb/?rub=39>.

14. Rieck T, Feig M, Delere Y, Wichmann O. Utilization of administrative data to assess the association of an adolescent health check-up with human papillomavirus vaccine uptake in Germany. *Vaccine*. 2014 Sep 29;32(43):5564-9.doi: 10.1016/j.vaccine.2014.07.105. PubMed PMID: 25131739.Epub 2014 Aug 12.
15. Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States. *MMWR Morb Mortal Wkly Rep*. 2014 Jul 25; 63(29): 620-4. PubMed PMID: 25055185
16. Firenze A, Marsala MG, Bonanno V, Maranto M, Ferrara C, Giovannelli L, et al. Facilitators and barriers HPV unvaccinated girls after 5 years of program implementation. *Hum VaccinImmunother*. 2014 Aug 27;11(1): 240-4. doi: 10.4161/hv.36158. PubMed PMID: 25483543. Epub 2014 Nov 1.
17. Ferrer HB, Trotter C, Hickman M, Audrey S. Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis. *BMC Public Health*.2014;14:700.doi: 10.1186/1471-2458-14-700. PubMed PMID: 25004868. Pubmed Central PMCID: 4100058.
18. Pathman DE, Konrad TR, Freed GL, Freeman VA, Koch GG. The awareness-to-adherence model of the steps to clinical guideline compliance.The case of pediatric vaccine recommendations. *Med.Care*. 1996 Sep;34(9):873-89. PubMed PMID: 8792778.
19. Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. *J Adolesc Health*. 2007 Feb; 40(2):108-15. PubMed PMID: 17259050. Epub 2006 Dec 6.
20. Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. *Pediatrics* 2006; 117(5): 1486-93. PubMed PMID: 16651301
21. Dahlström LA, Tran TN, Lundholm C, Young C, Sundström K, Sparén P. Attitudes to HPV vaccination among parents of children aged 12-15 years-a population-based survey in Sweden. *Int J Cancer*. Jan 15;126(2) : 500-7.doi: 10.1002/ijc.24712. PubMed PMID: 19569173
22. Donders GG, Gabrovskaja M, Bellen G, Van Keirsbilck J, Van Den Bosch Th, Riphagen I, Verjans M. Knowledge of cervix cancer, human papilloma virus (HPV) and HPV vaccination at the moment of introduction of the vaccine in women in Belgium. *Arch Gynecol Obstet*. 2008 Apr;277(4):291-8. PubMed PMID: 17965870. Epub 2007 Oct 27.
23. Donders GG, Bellen G, Declercq A, Berger J, Van Den Bosch T, Riphagen I, Verjans M. Change in knowledge of women about cervix cancer, human papilloma virus (HPV) and HPV vaccination due to introduction of HPV vaccines. *Eur J ObstetGynecolReprod Biol*. 2009 Jul;145(1):93-5.doi: 10.1016/j.ejogrb.2009.04.003. PubMed PMID: 19409688. Epub 2009 May 5.
24. Rose SB, Lawton BA, Lanumata T, Hibma M, Baker MG. HPV/cervical cancer vaccination: parental preferences on age, place and information needs. *J Prim Health Care*. 2010 Sep 1;2(3):190-8. PubMed PMID: 21069114
25. Ganry O, Bernin-Mereau AS, Gignon M, Merlin-Brochard J, Schmit JL. Human papillomavirus vaccines in Picardy, France: coverage and correlation with socioeconomic factors. *Rev EpidemiolSantePublique*. 2013 Oct;61(5):447-54. doi: 10.1016/j.respe.2013.04.005. PubMed PMID: 24016739.Epub 2013 Sep 7.
26. Lions C, Pulcini C, Verger P. Papillomavirus vaccine coverage and its determinants in South-Eastern France. *Med Mal Infect*.2013May;43(5):195-201.doi: 10.1016/j.medmal.2013.03.003. PubMed PMID: 23582828.Epub 2013 Apr 10.

27. Chauvin P, Valleron AJ. Participation of French general practitioners in public health surveillance: a multidisciplinary approach. *J Epidemiol Community Health*.1998 Apr;52 Suppl 1:2S-8S. PubMed PMID: 9764263.
28. carmf. La démographie sous surveillance. 2010 Sep. Available from: <http://www.carmf.fr/doc/publications/infocarmf/58-2010/stat1.htm>
29. Haut Conseil de la Santé Publique. Avis relatif à la révision de l'âge de vaccination contre les infections à papillomavirus humains des jeunes filles.2012 Sep. Available from: www.hcsp.fr/explore.cgi/hcspa20120928_agevaccpapilljeunesfilles.pdf.